Education
About Us
Working with TipRanks
Follow Us
Beta Bionics, Inc. (BBNX)
NASDAQ:BBNX
BBNX Stock Chart & Stats
$29.63
--
Market closed
$29.63
--
Day’s Range― - ―
52-Week Range$8.89 - $32.71
Previous CloseN/A
VolumeN/A
Average Volume (3M)917.05K
Market Cap
$1.30B
Enterprise Value$389.82M
Total Cash (Recent Filing)$228.69M
Total Debt (Recent Filing)$7.69M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 31, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding44,024,630
10 Day Avg. Volume410,323
30 Day Avg. Volume917,055
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)1.98
Price to Sales (P/S)2.31
P/FCF Ratio-2.91
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue4.40
Enterprise Value/Gross Profit8.07
Enterprise Value/Ebitda-5.96
Forecast
1Y Price Target
$31.83Price Target Upside7.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market PotentialBBNX is the farthest along in developing a pump with a fully-closed loop algorithm, which requires zero patient engagements and has potential to further unlock the big PCP market.
Pharmacy Channel GrowthBBNX's continued execution of its commercial strategy, particularly in pharmacy which continues to scale quicker than expected.
Product InnovationBBNX demonstrated its patch pump at the investor event, showing that the patch is fully operational and plans a broad launch once cleared and ready.
Bears Say
Market CompetitionRisks include the inability to gain market share against larger players and potential delays to patch timing.
Beta Bionics, Inc. News
BBNX FAQ
What was Beta Bionics, Inc.’s price range in the past 12 months?
Beta Bionics, Inc. lowest stock price was $8.89 and its highest was $32.71 in the past 12 months.
What is Beta Bionics, Inc.’s market cap?
Beta Bionics, Inc.’s market cap is $1.30B.
When is Beta Bionics, Inc.’s upcoming earnings report date?
Beta Bionics, Inc.’s upcoming earnings report date is Mar 31, 2026 which is in 103 days.
How were Beta Bionics, Inc.’s earnings last quarter?
Beta Bionics, Inc. released its earnings results on Oct 28, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.423 by $0.093.
Is Beta Bionics, Inc. overvalued?
According to Wall Street analysts Beta Bionics, Inc.’s price is currently Undervalued.
Does Beta Bionics, Inc. pay dividends?
Beta Bionics, Inc. does not currently pay dividends.
What is Beta Bionics, Inc.’s EPS estimate?
Beta Bionics, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Beta Bionics, Inc. have?
Beta Bionics, Inc. has 44,024,630 shares outstanding.
What happened to Beta Bionics, Inc.’s price movement after its last earnings report?
Beta Bionics, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.423. Following the earnings report the stock price went up 10.338%.
Which hedge fund is a major shareholder of Beta Bionics, Inc.?
Currently, no hedge funds are holding shares in BBNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beta Bionics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.83 (7.42% Upside)
$31.83 (7.42% Upside)
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $169.2K over
the Last 3 Months
the Last 3 Months
Fundamentals
Return on Equity
-47.52%
Trailing 12-Months
Asset Growth
35.99%
Trailing 12-Months
Company Description
Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
BBNX Company Deck
BBNX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented several positive developments, including strong revenue growth, an increase in new patient starts, and an expanded presence in the pharmacy channel. However, there were concerns about increased operating expenses, a notable churn rate, and potential uncertainties from CMS proposals. Overall, the positive aspects outweigh the negative, reflecting a strong quarter and optimistic future guidance.View all BBNX earnings summariesBBNX Stock 12 Month Forecast
Average Price Target
$31.83
▲(7.42% Upside)
Technical Analysis
Labcorp Holdings
―
Tandem Diabetes Care
―
Envista Holdings
―
Sana Biotechnology
―
Fortrea Holdings Inc.
―
Ownership Overview
9.78% Insiders
6.33% Mutual Funds
60.96% Other Institutional Investors
14.02% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---